Related Experiment Video
Updated: Oct 6, 2026
A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Making a mouse out of a molehill: how precision modeling repurposes drugs for congenital giant nevi
Katerina Grafanaki1, Glenn Merlino2, Chi-Ping Day2
1Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Dermatology, University Hospital of Patras, School of Medicine, University of Patras, Patras, Greece.
Abstract:
Patients with congenital giant nevi (CGN), which can compromise quality of life and progress to melanoma, have limited treatment options. Choi et al. have demonstrated that topical application of a proinflammatory hapten for alopecia treatment [squaric acid dibutylester (SADBE)] caused nevus regression and prevented melanoma in an Nras mouse CGN model. Their results demonstrate the promise of repurposing drugs through precision modeling.
Insights
Topical squaric acid dibutylester (SADBE), a treatment for alopecia, effectively reduced congenital giant nevi (CGN) and prevented melanoma in a mouse model. This study highlights drug repurposing potential for CGN treatment.
Area of Science:
- Dermatology
- Oncology
- Pharmacology
Background:
- Congenital giant nevi (CGN) pose significant quality of life challenges and carry a risk of melanoma.
- Current treatment options for CGN are limited, necessitating novel therapeutic approaches.
Purpose of the Study:
- To investigate the efficacy of squaric acid dibutylester (SADBE) in treating congenital giant nevi (CGN).
- To evaluate SADBE's potential in preventing melanoma development in a CGN mouse model.
Main Methods:
- Utilized an Nras mouse model of congenital giant nevi (CGN).
- Administered topical squaric acid dibutylester (SADBE), a known alopecia treatment, to the CGN model.
Main Results:
- Observed significant regression of congenital giant nevi (CGN) following SADBE treatment.
- Demonstrated prevention of melanoma development in the CGN mouse model treated with SADBE.
Conclusions:
- Topical SADBE shows promise as a therapeutic agent for congenital giant nevi (CGN).
- Drug repurposing, exemplified by SADBE for CGN, offers a viable strategy for treating rare dermatological conditions and preventing associated cancers.
More Related Videos
04:01Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
Published on: June 23, 2023
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
